PectaSol Modified Citrus Pectin Powder Super-Nutrient to Support Cellular & Immune Health, Joint Support - 454 Grams - Formulated by Dr. Isaac Eliaz of ecoNugenics

Product Information

J. Ibarrola, et al., “Galectin-3 Down-Regulates Antioxidant Peroxiredoxin-4 in Human Cardiac Fibroblasts: A New Pathway to Induce Cardiac Damage,” Clin. Sci. (Lond). 132(13), 1471–1485 (2018). Ried K, Eng P, Sali A. Screening for circulating tumour cells allows early detection of cancer and monitoring of treatment effectiveness: an observational study. Asian Pac J Cancer Prev. 2017 Aug 27;18(8):2275–85. DOI: 10.22034/APJCP.2017.18.8.2275. PMID: 28843267. PMCID: PMC5697492.

PectaSol-C (Modified Citrus Pectin) 150g – ecoNugenics

M. Azémar, et al., “Clinical Benefit in Patients with Advanced Solid Tumors Treated with Modified Citrus Pectin: A Prospective Pilot Study,” Clinical Med. Oncol. 1: https://doi.org/10.4137/CMO.S285 (2007).Inflammatory degenerative diseases — from cardiovascular disease and cancer to neurodegenerative disease and many others — continue to surpass epidemic magnitudes worldwide, challenging researchers to better understand upstream drivers and identify key therapeutic targets. Kolar, S. S., Barhoumi, R., Callaway, E. S., Fan, Y. Y., Wang, N., Lupton, J. R., et al. (2007). Synergy between docosahexaenoic acid and butyrate elicits p53-independent apoptosis via mitochondrial Ca(2+) accumulation in colonocytes. Am. J. Physiol. Gastrointest. Liver Physiol. 293, G935–G943. doi: 10.1152/ajpgi.00312.2007 Yan, J., and Katz, A. (2010). PectaSol-C modified citrus pectin induces apoptosis and inhibition of proliferation in human and mouse androgen-dependent and- independent prostate cancer cells. Integr. Cancer Ther. 9, 197–203. doi: 10.1177/1534735410369672 Sun H, Jiang H, Eliaz A, Kellum JA, Peng Z, Eliaz I. Galectin-3 in septic acute kidney injury: a translational study. Crit Care. 2021 Mar 18;25(1):109. DOI: 10.1186/s13054-021-03538-0. PMID: 33736691. PMCID: PMC7977587.

Letter to the Editor: Not all modified citrus pectins are the

The mechanical role of RG-I has been less studied but it seems that RG-I may play a role in cell wall plasticity, for example by preventing HG chains to interact with Ca 2 + ions. Transgenic plants with decreased amounts of arabinans and galactans display a stiffening of their cell wall. Chemoresistance is a heavy burden in the treatment of cancer, especially since a large number of patients already display metastatic disease at the time of diagnosis. The vast majority of anti-cancer drugs currently used act by inducing apoptosis via the intrinsic pathway. Numerous mechanisms underlie cancer chemoresistance ( Rebucci and Michiels, 2013), but it appears that galectin-3 which is overexpressed in numerous tumor types, suppresses cell apoptosis and hence, decreases sensitivity of cancer cells to chemotherapeutic drugs ( Glinsky and Raz, 2009). Since MCP has been shown to target galectin-3, several works were dedicated to delineate MCP-induced possible re-sensitization of cancer cells to different cytotoxic molecules. Johnson et al. (2007) showed that galectin-3 targeting via MCP or via a more specific inhibitor, lactosyl- L-leucine (LL), decreased malignant endothelial cell proliferation by themselves and sensitized these cells to the cytotoxic effect of doxorubicin. These two compounds also increases metastatic-derived MDA-MB-435 cells sensitivity to taxol both in vitro and in vivo ( Glinsky et al., 2009). GCS-100, a commercially form of pH-MCP, enhanced bortezomide and dexamethasone-induced apoptosis in multiple myeloma cells and decreased viability. The effect was accompanied by a marked decrease in galectin-3 protein level ( Chauhan et al., 2005). GCS-100 also induced calpain activation in prostate cancer cells that led to their sensitization to cisplatin treatment ( Wang et al., 2010). Combination of modified pectin with different anti-cancer agents may thus represent an efficient new strategy to overcome resistance in cancer patients. Use of Pectin as a Vehicle for Drug Delivery in CancerPectaSol-C® Professional Lime Modified Citrus Pectin is a great tasting and convenient way for your patients to get the scientifically substantiated benefits of PectaSol-C Professional Modified Citrus Pectin. With real lime and a touch of stevia, PectaSol-C Professional Lime mixes well and tastes great, making it even easier for consumers to maintain protocol objectives and achieve their health goals.* PectaSol is the ONLY available agent shown to halt the actions of “rogue protein” galectin-3 (Gal-3). Over 8,000 published studies, including large-scale clinical data, demonstrate how elevated Gal-3 impacts cellular health, cardiovascular health, kidney and liver function, immunity, and much more. Gal-3 is normally present in small amounts throughout the body, however, levels increase with age and oth